# A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer

Source: https://onco.cc/trials/nct06568094/  
OnCo record `nct06568094` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

This study tests a PARP inhibitor; the registry reports that it is recruiting.

## Summary

The registry lists NCT06568094 as recruiting, last updated 2026-09-17. Enrolment is 100 planned participants, an estimate. Interventions: HRS-5041 tablets, Abiraterone Acetate tablets（II）, Prednisone Acetate tablets, Docetaxel Injection, HRS-1167 tablets, SHR2554 tablets, HRS-6208 capsules, HRS-2189 Tablets. Primary measures include Recommended phase II dose (Phase Ib); Incidence and severity of adverse events (AE) (Phase Ib). No results are posted in the registry; this does not exclude separate publications.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-10-06
- Tags: ctgov-ingest
- Registry id: NCT06568094
- Phase: 1/2
- Setting: An Open, Multicenter Phase Ib/II Study on the Safety, Tolerability and Efficacy of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer
- Sponsor: Jiangsu HengRui Medicine Co., Ltd.

## Sources

- ClinicalTrials.gov NCT06568094: https://clinicaltrials.gov/study/NCT06568094

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- targets: [PARP](https://onco.cc/targets/parp/)
- drugs: [Darolutamide](https://onco.cc/drugs/darolutamide/), [Docetaxel](https://onco.cc/drugs/docetaxel/), [HRS-1167](https://onco.cc/drugs/hrs-1167/), [Prednisone](https://onco.cc/drugs/prednisone/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)

---
JSON: https://onco.cc/api/v1/entities/nct06568094.json